Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIX100 in Healthy Subjects
NCT06800729Phase 1Recruiting
- Sponsor
- TIXiMED
- Start
- Jan 2025
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TIX100 in type 1 diabetes mellitus (T1D) (6 arms), sponsored by TIXiMED. Primary endpoints: Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 at Day 7, Number of participants with laboratory analyte results above upper limit of normal at Day 7 and 3 more. Started Jan 2025; status: recruiting.
02
Drugs
TIX100
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT06800729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06800729.